Cytomegalovirus: An Overlooked Herpesvirus in Post-Viral and Chronic Disease Research
Research into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has frequently examined the possible involvement of Epstein–Barr virus (EBV), particularly because some patients report the onset of prolonged illness following infectious mononucleosis or another acute viral illness. However, EBV is only one member of the human herpesvirus family.
Another widespread herpesvirus deserving consideration in research into immune dysregulation and post-infectious disease is human cytomegalovirus (HCMV or CMV), also known as human herpesvirus 5 (HHV-5).
CMV is extremely common. In most immunocompetent people, primary infection causes either no symptoms or a relatively mild mononucleosis-like illness. Once acquired, however, CMV is not eliminated from the body. Like other herpesviruses, it establishes lifelong latency and can reactivate under certain circumstances.
The COVID-19 pandemic has renewed scientific interest in herpesvirus reactivation during and after major infections. CMV, EBV, and other latent herpesviruses have consequently been investigated as possible contributors to complicated acute illness, altered immune responses, and persistent post-infectious symptoms.
This remains an evolving area of research. Evidence of CMV antibodies—or even evidence suggesting viral reactivation in a particular clinical setting—does not by itself demonstrate that CMV causes ME/CFS, Long COVID, or another chronic post-infectious illness. Establishing causation requires substantially stronger evidence.
CMV Infection and Symptoms
The clinical presentation of CMV varies considerably according to age, immune status, and whether infection is primary, latent, or reactivated.
Healthy Individuals
Most healthy people infected with CMV have no recognizable symptoms. When symptomatic primary infection occurs, it can resemble infectious mononucleosis and may include:
Fever
Marked fatigue
Sore throat
Swollen lymph nodes
Muscle or joint aches
General malaise
The resulting illness can sometimes be difficult to distinguish clinically from other viral infections without laboratory testing.
Immunocompromised Individuals
CMV assumes much greater clinical importance in people with substantially weakened immune systems, including some organ or stem-cell transplant recipients, people with advanced HIV infection, and patients receiving intensive immunosuppressive treatment.
In these circumstances, CMV can cause serious organ disease, including retinitis, which can impair vision; pneumonitis or pneumonia, which can compromise respiratory function; gastrointestinal disease, including esophagitis and colitis; and, less commonly, central nervous system involvement, such as encephalitis.
The biology and clinical significance of CMV in severely immunocompromised patients should not automatically be extrapolated to otherwise immunocompetent people with chronic post-viral symptoms.
Congenital CMV
CMV can also be transmitted from a pregnant person to the developing fetus. Congenital CMV represents a distinct and important clinical problem.
Many infants with congenital CMV are asymptomatic at birth, while others develop significant complications. Potential manifestations include:
Sensorineural hearing loss
Low birth weight
Microcephaly
Jaundice
Enlarged liver or spleen
Petechiae or purpuric skin lesions
Neurological and developmental impairment
Hearing loss is particularly important because it may be present at birth or develop later.
How CMV Spreads
CMV is transmitted through infected body fluids, including saliva, urine, blood, breast milk, semen, and vaginal secretions. Transmission can therefore occur through close interpersonal contact, sexual contact, blood or organ exposure, breastfeeding, and vertical transmission during pregnancy.
After primary infection, the immune system usually suppresses active viral replication but does not eradicate the virus.
Latency and Reactivation: Why CMV Is Scientifically Interesting
The lifelong persistence of CMV is one reason the virus is relevant to research on immune regulation.
Latency is not the same as continuous active infection. During latency, infectious virus is not simply replicating throughout the body at the level seen during acute CMV disease. Instead, the viral genome persists within particular cell populations and can potentially resume productive replication when biological conditions permit.
Reactivation is well established in immunocompromised patients. More subtle interactions between latent CMV and the immune system in otherwise immunocompetent people are scientifically interesting but much more difficult to interpret.
CMV also has an unusually extensive relationship with the human immune system. Lifelong infection can shape T-cell populations and other components of immune function. This makes CMV relevant not only as an infectious agent but also as a potential modifier of immune biology.
That distinction is important. A virus can influence immune characteristics without necessarily being the direct cause of a patient's chronic disease.
CMV, ME/CFS, and Long COVID
ME/CFS is characterized by symptoms that can include profound impairment in function, post-exertional malaise, unrefreshing sleep, cognitive difficulties, and autonomic manifestations. Infectious illnesses are among the reported triggers.
Consequently, researchers have investigated several herpesviruses—including EBV, CMV, and human herpesvirus 6 (HHV-6)—as possible factors in subsets of patients.
The emergence of Long COVID has provided another context in which latent-virus reactivation is being studied. Severe acute infections can substantially alter immune activity, and SARS-CoV-2 infection has prompted investigation into whether reactivation or altered immune responses to persistent herpesviruses accompany some acute or post-acute disease states.
Several fundamentally different hypotheses need to be distinguished:
A herpesvirus might reactivate and directly contribute to symptoms.
Reactivation might occur because the immune system has already been disrupted by another disease process.
Previous CMV infection might alter immune responses to a subsequent infection without itself reactivating.
CMV-related biomarkers might correlate with illness without playing a causal role.
These mechanisms are not interchangeable, and distinguishing among them is essential before drawing clinical conclusions.
Interpreting CMV Tests
CMV can be investigated using several laboratory methods, but each answers a different question.
CMV IgG antibodies generally indicate previous exposure. Because CMV infection is common, a positive IgG result alone usually provides little evidence that CMV is responsible for current symptoms.
CMV IgM antibodies can occur during recent primary infection but require careful interpretation because IgM results are not always synonymous with newly acquired infection.
PCR testing detects CMV DNA and can be extremely useful in appropriate clinical settings, particularly when evaluating active infection in immunocompromised patients.
Other tests, including antigen assays and tissue-based testing, may be appropriate depending on the clinical situation.
The key principle is that past exposure, immune response, viral reactivation, active viral replication, tissue-invasive CMV disease, and CMV causing a chronic multisystem illness are different propositions requiring different evidence.
Treatment of CMV
Clinically significant CMV disease can be treated with antiviral drugs, particularly in high-risk or immunocompromised patients.
Agents used against CMV include:
Ganciclovir
Valganciclovir
Foscarnet
Cidofovir
Maribavir in selected settings
These are potent medicines with potentially important adverse effects and are not treatments that should be used simply because someone has CMV antibodies.
CMV also differs pharmacologically from herpes simplex virus and varicella-zoster virus. Acyclovir has relatively weak activity against CMV and is not a standard treatment for CMV disease. The molecular biology underlying antiviral susceptibility is more complicated than simply saying that CMV entirely “lacks thymidine kinase”: CMV encodes the UL97 protein kinase, which plays an important role in activating ganciclovir.
This distinction leads to another topic that can easily become confused with viral thymidine-kinase biology: the human mitochondrial enzyme thymidine kinase 2 (TK2).
TK2 Deficiency: A Separate Mitochondrial Disease
Despite the similarity in terminology, human TK2 deficiency should not be conflated with CMV infection or CMV antiviral pharmacology.
The human TK2 gene encodes mitochondrial thymidine kinase 2, an enzyme involved in the mitochondrial salvage pathway that supplies nucleotides required for mitochondrial DNA maintenance.
Pathogenic variants affecting both copies of TK2 can cause TK2-related mitochondrial DNA maintenance disorder, commonly referred to as thymidine kinase 2 deficiency (TK2d).
This is an inherited mitochondrial disorder—not a herpesvirus infection.
What Happens in TK2 Deficiency?
TK2 deficiency is generally inherited in an autosomal recessive manner. Affected individuals have pathogenic variants affecting both copies of the TK2 gene.
Insufficient TK2 activity disrupts the supply of nucleotides required for normal mitochondrial DNA maintenance. Depending on the phenotype, this can result in mitochondrial DNA depletion, multiple mitochondrial DNA deletions, or both.
Because mitochondria are responsible for much of cellular energy production, tissues with high energy requirements—particularly skeletal and respiratory muscle—can be severely affected.
Clinical Features
TK2-related disease encompasses a spectrum rather than a single uniform presentation.
Early-onset disease can cause rapidly progressive muscle weakness, feeding difficulties, loss of motor abilities, and respiratory impairment.
Childhood- and later-onset forms can progress more slowly. Manifestations may include:
Progressive skeletal-muscle weakness
Respiratory-muscle weakness
Exercise intolerance
Dysphagia
Ptosis
Ophthalmoparesis
Loss of previously acquired motor abilities
Swallowing dysfunction is particularly important because severe dysphagia can increase the risk of aspiration, malnutrition, and respiratory complications.
Genetics and TK2 Variants
Numerous variants have been described in the TK2 gene. Some are pathogenic, while many other genetic variants are benign or of uncertain significance.
An rs number in a database such as dbSNP is simply a reference identifier for a genetic variant. The existence of an rs number does not establish that a variant causes disease.
For an individual genetic result, interpretation therefore requires the precise variant, zygosity, classification, population frequency, clinical phenotype, inheritance pattern, and supporting functional or clinical evidence.
This is particularly important for recessive diseases such as TK2 deficiency, in which identifying one pathogenic variant does not ordinarily establish the diagnosis by itself.
Diagnosis and Treatment
Diagnosis of TK2-related disease relies primarily on molecular genetic testing, interpreted together with clinical findings. Muscle biopsy, mitochondrial DNA studies, biochemical investigations, imaging, respiratory assessment, and other tests may provide additional evidence depending on the case.
Management can require a multidisciplinary team, particularly for respiratory weakness, impaired mobility, nutrition, and swallowing difficulties.
Nucleoside-based treatment has become an important area of TK2 research and therapy. The underlying concept is to provide nucleosides that can help bypass the metabolic bottleneck created by deficient TK2 activity and improve the availability of building blocks needed for mitochondrial DNA maintenance.
The Important Distinction Between CMV and TK2
The appearance of the term “thymidine kinase” in both antiviral pharmacology and mitochondrial medicine can create an attractive but potentially misleading connection.
They concern fundamentally different biological systems.
CMV is a herpesvirus. TK2 is a human nuclear gene encoding a mitochondrial enzyme. TK2 deficiency is a rare inherited mitochondrial disease.
At present, the fact that CMV antiviral pharmacology involves viral nucleotide-processing enzymes does not establish a mechanistic relationship between CMV infection and inherited TK2 deficiency.
The distinction is particularly important when considering chronic illnesses characterized by fatigue, exercise intolerance, muscle symptoms, or impaired energy metabolism. Similar symptoms can emerge from very different biological mechanisms.
Why CMV Deserves Further Study
CMV remains an intriguing candidate for further investigation in post-infectious disease—not because it has been demonstrated to cause ME/CFS or Long COVID, but because several features make it biologically relevant.
It is extraordinarily widespread, establishes lifelong persistence, interacts extensively with the immune system, can reactivate under physiological stress or immunosuppression, and produces measurable changes in immune-cell populations.
Future research could therefore ask more precise questions: Are particular CMV immune signatures disproportionately present in defined patient subgroups? Is genuine viral reactivation occurring, rather than simply altered antibody levels? Does CMV infection modify immune responses to SARS-CoV-2 or other triggering infections? Do longitudinal changes in CMV biomarkers correlate with symptoms, and—most importantly—does experimentally modifying CMV activity change disease outcomes?
Those questions require longitudinal studies, carefully characterized patient populations, appropriate control groups, direct measures of viral activity, and mechanistic experiments.
Conclusion
CMV deserves greater attention in research into post-infectious illness, but attention should not be confused with attribution.
The virus is common, persistent, immunologically active, and capable of reactivation. Those characteristics make it a plausible subject of investigation in conditions involving immune dysregulation. They do not establish CMV as the cause of ME/CFS, Long COVID, or other chronic syndromes.
The same caution applies when exploring mitochondrial biology. TK2 deficiency demonstrates how profoundly disruption of nucleotide metabolism and mitochondrial DNA maintenance can affect muscle function and cellular energy production. Yet TK2 deficiency is a specific inherited genetic disorder and should not be presented as a demonstrated consequence of CMV infection.
The scientifically useful approach is therefore not to assume a single explanation, but to investigate the intersections among persistent viruses, immune regulation, mitochondrial function, and post-infectious disease while maintaining a clear distinction between established mechanisms, emerging associations, and hypotheses still awaiting experimental confirmation.
References:
Complications:
https://www.rarediseaseadvisor.com/disease-info-pages/thymidine-kinase-2-deficiency-complications/
The
impact of TK2 deficiency syndrome and its treatment by nucleoside therapy on
quality of life
https://pubmed.ncbi.nlm.nih.gov/36374792/
Cytomegalovirus
(CMV) infection
https://www.mayoclinic.org/diseases-conditions/cmv/symptoms-causes/syc-20355358
Does
reactivation of cytomegalovirus contribute to severe COVID-19 disease?
https://pmc.ncbi.nlm.nih.gov/articles/PMC7952506/
Diet: Thymidine
Kinase 2 Deficiency (TK2d)
https://www.rarediseaseadvisor.com/hcp-resource/thymidine-kinase-2-deficiency-diet-nutrition/
Complications: https://www.rarediseaseadvisor.com/disease-info-pages/thymidine-kinase-2-deficiency-complications/
Comments
Post a Comment